Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore function in New Zealand. Its lead product is NTCELL, an alginate coated capsule, which is in Phase IIb clinical trial for the treatment of Parkinson's disease. In addition to this, NTCELL has the potential to be used in a number of other central nervous system indications, including Huntington's and Alzheimer's. The company was founded in 1987 and is based in Auckland, New Zealand.